Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...

Outcomes of veterans diagnosed with chronic myeloid leukemia in the tyrosine kinase inhibitor era. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

Association of frailty with annual healthcare expenditures of older adults during cancer survivorship. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does ...

Of 38 efficacy-evaluable patients, the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks, with 64% (18/28) achieving MMR and 100% (10/10) maintaining MMR. Also Read: ...

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...